Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...

Novavax NVAX announced a non-exclusive license agreement with Pfizer PFE, granting the latter access to its proprietary ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Gaithersburg’s Novavax has struck a deal to give Pfizer the rights to its adjuvant technology — for a potential $530 million ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Novavax can ...

The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine but with unusual restrictions. Novavax makes the nation’s only traditional protein-based coronavirus ...

Novavax’s CEO reviewed the company’s successes in 2025 and shared its growth strategy for 2026 and beyond at a recent ...

FILE - A vial of the Phase 3 Novavax coronavirus vaccine is seen ready for use in the trial at St. George's University hospital in London, Oct. 7, 2020. The Novavax COVID-19 vaccine that could soon ...

Regulatory uncertainty remains a common factor for both companies following an FDA memo that raised concerns about vaccine ...